Exchange: NASDAQ·Updated 07:30 PM EDT
GMAB logo

GMAB Genmab - ADR

$32.47
$0.24
(0.74%)
Today
Closed $32.47
$0.04
(0.12%)
After Hours
EarningsNov 5
Mkt Cap$19.39B
Vol1.39M

About GMAB

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
51

Neutral Sentiment

How do you feel about GMAB?

Advertisement|Remove ads.